Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ortho-hydroxybenzoic acid or derivative doai
Reexamination Certificate
2001-09-18
2002-08-20
Killos, Paul J. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ortho-hydroxybenzoic acid or derivative doai
C560S143000, C502S400000, C514S165000, C514S229800, C514S223800, C514S224200, C514S532000
Reexamination Certificate
active
06436916
ABSTRACT:
TECHNICAL FIELD
This invention is directed to aralkyl esters (more preferably alkaralkyl esters) of salicylic acid and their use in treating aspirin or ibuprofen-treatable conditions. This invention is also directed at hydroxymethylacylfulvene analogs and their use as antitumor drugs.
BACKGROUND OF THE INVENTION
Aspirin (acetylsalicylic acid), one of the oldest over-the-counter drugs having been marketed since 1899, continues to be used for relief from headaches, fevers and arthritis pain. Aspirin works as an analgesic to reduce pain, an anti-pyretic to reduce fever and an anti-inflammatory agent. Recently, aspirin has been shown to aid in the prevention of heart attacks. However, aspirin does have undesirable side effects. Use of aspirin has been linked to Reye's Syndrome in children, hearing impairment in heavy users, stomach problems, excessive bleeding and certain rare but serious complications of pregnancy.
Other anti-inflammatory drugs that reduce pain such as acetaminophen (under the trade name Tylenol) and ibuprofen (under the trade names Motrin, Advil and Nuprin) are also available. However, these also are associated with potentially harmful side effects. Acetaminophen, the most preferred analgesic after aspirin, can cause delayed liver damage when used excessively and major kidney damage with long-term chronic use. Accordingly, there is still a need for analgesic, anti-pyretic and anti-inflammatory drugs that can be used in place of aspirin, ibuprofen and acetaminophen.
A listing of human cancers for which chemotherapy has exerted a predominant role in increasing life span, approaching normal life expectancy, includes Burkitt's lymphoma, acute lymphocytic leukemia and Hodgkin's disease, along with about 10-15 other tumor types. See, for example, Golden et al.,
Eur. J Cancer
, 12, 129 (1981) (Table 1). While the cure rate of these cancers illustrates the level of success of screening systems in selecting antitumor agents that are effective in man, these responsive tumors represent only a small fraction of the various types of cancer and, notably, there are relatively few drugs highly active against clinical solid tumors. Such drugs include cyclophosphamide, adriamycin, 5-FU, hexamethylmelamine and the like. Thus, patients with many types of malignancies remain at significant risk for relapse and mortality.
After relapse, some patients can be reinduced into remission with their initial treatment regimen. However, higher doses of the initial chemotherapeutic agent or the use of additional agents are frequently required, indicating the development of at least partial drug resistance. Recent evidence indicates drug resistance can develop simultaneously to several agents, including ones to which the patient was not exposed. The development of multiple-drug resistant (MDR) tumors may be a function of tumor mass and constitutes a major cause of treatment failure. To overcome this drug resistance, high-dose chemotherapy with or without radiation and allogenic or autologous bone marrow transplantation can be employed. The high-dose chemotherapy may employ the original drug(s) or be altered to include additional agents. The development of new drugs non-cross resistant with MDR phenotypes is required to further the curative potential of current regimens and to facilitate curative interventions in previously treated patients.
Recently, the in vitro anti-tumor activity of a novel class of natural products called illudins has been examined. See Kelner et al.,
Cancer Res
., 47, 3186 (1987). The extreme toxicity of illudins has prevented any applications in human tumor therapy. Recently, synthetic analogs of the illudins have been developed which exhibit promising antitumor activity. See, for example, U.S. Pat. No. 5,439,936 (Kelner et al), issued Aug. 8, 1995 and U.S. Pat. No. 5,523490 (Kelner et al), issued Jun. 4, 1996. These include hydroxymethylacylfluvene (HMAF) which has recently shown promise as an antitumor drug. See Zurer,
Chem. Eng. News
, page 7 (Feb. 10, 1997) However, there still exists a continuing need for chemotherapeutic agents which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment.
SUMMARY OF THE INVENTION
The present invention relates to ibuprofen-aspirin compounds useful in treating various conditions previously treated with aspirin or ibuprofen and which have the formula I:
wherein R
1
is hydrogen, benzoyl or alkyl, e.g., lower alkyl of 1 to 6 carbon atoms, and preferably is a branched chain alkyl, e.g., isoalkyl, sec-alkyl or tert-alkyl; R
2
and R
3
are hydrogen or lower alkyl, e.g. methyl, ethyl or propyl, preferably R
2
is hydrogen and R
3
is methyl; n is zero or a small integer, e.g., 1, 2, or 3; R
4
and R
5
are hydrogen or lower alkyl, preferably hydrogen or methyl; R
6
and R
7
are as defined for R
1
and are preferably hydrogen; and X is hydrogen or a pharmaceutically acceptable salt forming metal or group (advantageously, the sodium, potassium, lithium, calcium or ammonium salts). When R
1
is alkyl, it is preferably in the para position but can be in the ortho or meta position. When R
1
is benzoyl, it is preferably in the meta position. An example of such a compound is the phenolic acid ester of ketoprofen(2-(3-benzoylphenyl)-propionic acid.
The present invention also relates to hydroxymethylacylfulvene analog compounds useful as antitumor drugs and which have the formula II:
wherein R
8
is an acyl group of an acid having at least 3 carbon atoms, the acid being selected from alkenoic acids having 1 to 6 ethylenic double bonds, phenoxyalkanoic acids, ring halogenated phenoxyalkanoic acids having 1 to 3 ring halogen atoms, alkylidene bis-phenoxyalkanoic acids and alkylidene bis-ring halogenated phenoxyalkanoic acids having 1 to 3 ring halogen atoms in each ring; R
9
is hydrogen, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 4 carbon atoms, preferably hydrogen; each R
10
, R
11
, and R
12
is an alkyl group having 1 to 4 carbon atoms, preferably a methyl group; and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 3220960 (1965-11-01), Wicterle et al.
patent: 3228831 (1966-01-01), Nicholson et al.
patent: 3385886 (1968-05-01), Nicholson et al.
patent: 3630715 (1971-12-01), Guttag
patent: 4643995 (1987-02-01), Engel et al.
patent: 5439936 (1995-08-01), Kelner et al.
patent: 5523490 (1996-06-01), Kelner et al.
patent: 5563176 (1996-10-01), Kelner et al.
patent: 5723632 (1998-03-01), McMorris
patent: 5760261 (1998-06-01), Guttag
patent: 5856580 (1999-01-01), McMorris
patent: 5910511 (1999-06-01), Guttag
patent: 5932553 (1999-08-01), McMorris et al.
patent: 6025328 (2000-02-01), McMorris et al.
patent: 6037338 (2000-03-01), Guttag
patent: 6069283 (2000-05-01), McMorris et al.
patent: 6160184 (2000-12-01), McMorris
patent: 158430 (1975-06-01), None
patent: 1814607 (1968-07-01), None
patent: 2049647 (1994-04-01), None
patent: 1575571 (1969-07-01), None
patent: 1584915 (1970-01-01), None
patent: 2044356 (1971-02-01), None
Dong et al, The Journal of Biological Chemistry, vol. 272, No. 15, pp. 9962-9970.*
Gilbert et al., Journal of Chemical Research, vol. 7, 1977, 172.*
CA vol. 71, No. 123843 a New derivatives of Phenylacetic acid used as antiinflammatory agents, 1969, Aries Robert.*
Arnst, “Aspirin Takes on a New Job: Fighting Colon Cancer,”Business Week, (Jun. 15, 1998). p. 132.
Hrabak et al,Chem. Abst.vol. 84 p. 430 item 16972p.
Maruko Pharm. Co.,Chem Abst., 94, (1981), p. 544, 46974q.
Pala et al, “Terpene Compounds as Drugs: Terpenyl Derivatives of Salicylic Acid,”J. Med. Chem., 11:4 (1968) pp. 910-911.
Prouix, “Scientists Debate Change in Infant Formula,”The Washington Post, Health Section, (Mar. 4, 1997), p. 19.
Reyes et al.,Chem Abst., 101, (1984), p. 574, 6756b.
Rovner, “Aspirin: New Tricks for an Old Drug,”The Washington Post(Article was received incomplete only pp. 10, 12).
Zurer, “Total Synthesis Yields Anticancer Drug,” Chem Eng. News, (Feb. 10, 1997), pp. 7-8.
Dong et al, The Journal of Biologic
Guttag Eric W.
Killos Paul J.
Reyes Hector M
Smith, Guttag, Hasse & Nesbitt Ltd
LandOfFree
Ibuprofen-aspirin and hydroxymethylacylfulvene analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ibuprofen-aspirin and hydroxymethylacylfulvene analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ibuprofen-aspirin and hydroxymethylacylfulvene analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2971579